UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Quality of Life After Open or Robotic Prostatectomy, Cryoablation or Brachytherapy for Localized Prostate Cancer

The Journal of urology, 2010-05, Vol.183 (5), p.1822-1829

2010

Link zum Volltext

Verfügbarkeit prüfen

Using Preoperative Albumin Levels As a Surrogate Marker for Outcomes After Radical Cystectomy for Bladder Cancer

Urology (Ridgewood, N.J.), 2013-03, Vol.81 (3), p.587-592

2013

Link zum Volltext

Verfügbarkeit prüfen

Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study

European journal of cancer (1990), 2023-11, Vol.193, p.113290-113290, Article 113290

2023

Link zum Volltext

Verfügbarkeit prüfen

Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement

European urology, 2023-12, Vol.84 (6), p.547-560

2023

Link zum Volltext

Verfügbarkeit prüfen

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

Future oncology (London, England), 2024-03, Vol.20 (10), p.563-578

2024

Link zum Volltext

Verfügbarkeit prüfen

Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry

Journal of endourology, 2016-01, Vol.30 (1), p.43

2016

Link zum Volltext

Verfügbarkeit prüfen

MP18-03 PREDICTORS OF LOCAL DISEASE CONTROL AFTER SALVAGE WHOLE GLAND PROSTATE CRYOABLATION

The Journal of urology, 2016-04, Vol.195 (4), p.e193-e193

2016

Link zum Volltext

Verfügbarkeit prüfen

Achieving the ‘bifecta’ using salvage cryotherapy for locally recurrent prostate cancer: analysis of the Cryo On‐Line Data (COLD) Registry data

BJU international, 2012-07, Vol.110 (2), p.217-220

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease

Journal of proteomics, 2009-08, Vol.72 (6), p.907-917

2009

Link zum Volltext

Verfügbarkeit prüfen

Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation

Journal of endourology, 2017-05, Vol.31 (5), p.497

2017

Link zum Volltext

Verfügbarkeit prüfen

Robotic-Assisted Ureteral Re-implantation: A Case Series

Journal of laparoendoscopic & advanced surgical techniques. Part A, 2015-06, Vol.25 (6), p.503

2015

Link zum Volltext

Verfügbarkeit prüfen

1344 INFLUENCE OF PREOPERATIVE PELVIC FLOOR MUSCLE STRENGTH ON POST-PROSTATECTOMY INCONTINENCE

The Journal of urology, 2012-04, Vol.187 (4), p.e545-e545

2012

Link zum Volltext

Verfügbarkeit prüfen

1300 DOES NEOADJUVANT HORMONE THERAPY PRIOR TO PRIMARY WHOLE GLAND CRYOABLATION OF THE PROSTATE AFFECT OUTCOME?

The Journal of urology, 2011-04, Vol.185 (4), p.e520-e520

2011

Link zum Volltext

Verfügbarkeit prüfen

Single center experience with percutaneous and laparoscopic cryoablation of small renal masses

Journal of endourology, 2009-06, Vol.23 (6), p.907

2009

Link zum Volltext

Verfügbarkeit prüfen

Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life

Journal of endourology, 2007-12, Vol.21 (12), p.1521

2007

Link zum Volltext

Verfügbarkeit prüfen

Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution

Journal of endourology, 2006-10, Vol.20 (10), p.723

2006

Link zum Volltext

Verfügbarkeit prüfen

Renal functional outcomes after cryoablation of small renal masses

Journal of endourology, 2010-03, Vol.24 (3), p.479

2010

Link zum Volltext

Verfügbarkeit prüfen

Modified running vesicourethral anastomosis after robotically assisted laparoscopic radical prostatectomy: Use of solitary Lapra-Ty to secure posterior approximation

Urology (Ridgewood, N.J.), 2005-07, Vol.66 (1), p.16-18

2005

Link zum Volltext

Verfügbarkeit prüfen

Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases

Urology (Ridgewood, N.J.), 2005-11, Vol.66 (5), p.1054-1059

2005

Link zum Volltext

Verfügbarkeit prüfen

Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer

Journal of endourology, 2005-04, Vol.19 (3), p.318-326

2005

Link zum Volltext

Verfügbarkeit prüfen

PD01-03 THIRD INTERIM ANALYSIS (IA3) OF THE DAROLUTAMIDE OBSERVATIONAL (DAROL) STUDY IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Link zum Volltext

Verfügbarkeit prüfen

Computer Modeling Technology to Assess Extracapsular Tissue Coverage of Whole Mount Sections After Retropubic and Laparoscopic Radical Prostatectomy

The Journal of urology, 2007-10, Vol.178 (4), p.1301-1305

2007

Link zum Volltext

Verfügbarkeit prüfen

PD10-11 APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES

The Journal of urology, 2020-04, Vol.203 (Supplement 4)

2020

Link zum Volltext

Verfügbarkeit prüfen

Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.82-82

2020

Link zum Volltext

Verfügbarkeit prüfen

TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.TPS389-TPS389

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(32)

Publikationsform

Sprache

Englisch
(58)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Quality of Life After Open or Robotic Prostatectomy, Cryoablation or Brachytherapy for Localized Prostate Cancer

Using Preoperative Albumin Levels As a Surrogate Marker for Outcomes After Radical Cystectomy for Bladder Cancer

Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study

Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry

MP18-03 PREDICTORS OF LOCAL DISEASE CONTROL AFTER SALVAGE WHOLE GLAND PROSTATE CRYOABLATION

Achieving the ‘bifecta’ using salvage cryotherapy for locally recurrent prostate cancer: analysis of the Cryo On‐Line Data (COLD) Registry data

Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease

Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation

Robotic-Assisted Ureteral Re-implantation: A Case Series

1344 INFLUENCE OF PREOPERATIVE PELVIC FLOOR MUSCLE STRENGTH ON POST-PROSTATECTOMY INCONTINENCE

1300 DOES NEOADJUVANT HORMONE THERAPY PRIOR TO PRIMARY WHOLE GLAND CRYOABLATION OF THE PROSTATE AFFECT OUTCOME?

Single center experience with percutaneous and laparoscopic cryoablation of small renal masses

Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life

Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution

Renal functional outcomes after cryoablation of small renal masses

Modified running vesicourethral anastomosis after robotically assisted laparoscopic radical prostatectomy: Use of solitary Lapra-Ty to secure posterior approximation

Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases

Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer

PD01-03 THIRD INTERIM ANALYSIS (IA3) OF THE DAROLUTAMIDE OBSERVATIONAL (DAROL) STUDY IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)

Computer Modeling Technology to Assess Extracapsular Tissue Coverage of Whole Mount Sections After Retropubic and Laparoscopic Radical Prostatectomy

PD10-11 APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES

Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)

TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Suchergebnisse filtern